High-dose short-term osimertinib treatment is effective in patient-derived metastatic colorectal cancer organoids
{{output}}
Background: Most tyrosine kinase inhibitors (TKIs) have failed in clinical trials for metastatic colorectal cancer (mCRC). To leverage the additional lower-affinity targets that most TKIs have, high-dose regimens that trigger eff... ...
